JAK2 Gene, V617F Mutation, Quantitative
0040168
Ordering Recommendation
Quantitates JAK2 V617F allele frequency in enriched granulocytes from peripheral whole blood.  Aids in risk stratification and therapeutic monitoring of JAK2 V617F mutation positive myeloproliferative neoplasms.
Mnemonic
JAK2 QNT
Methodology
Polymerase Chain Reaction
Performed
DNA isolation: Sun-Sat
Assay:
Mon, Wed, Fri
Reported
7-10 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA).  
Specimen Preparation
Transport 5 mL whole blood. (Min: 1 mL)..  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Bone marrow, serum, or plasma. Frozen or clotted whole blood. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
  
Stability
Ambient: 24 hours; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
81270
Components
Component Test Code*Component Chart NameLOINC
0040167JAK2 Gene, V617F Mutation, Quantitative53761-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • BCR-ABL1-negative tesing
  • Classic BCR-ABL1-negative MPN testing
  • MPN JAK 2
  • mutant JAK 2 V617F allelic burden